Dominik Altevogt, Ph.DAssociate Director Regulatory Affairs CMC at F.Hoffmann-La Roche Ltd
During over 10 years in the pharmaceutical industry, Dominik Altevogt has led multiple regulatory submissions and health authority interactions for small molecule drugs, with special focus on synthetic peptides and oligonucleotides. He started his career in the field of CMC regulatory affairs working for a peptide/oligonucleotide manufacturer. From 2014 to 2021, Dominik was working for F. Hoffmann-La Roche AG in Basel as a CMC Regulatory Manager. In 2021, he joined Novartis as Associate Director Regulatory Affairs CMC. Dominik holds a Ph.D. in organic chemistry from the University of Freiburg, Germany.